Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis

Journal of Infection and Public Health

Melissa C. Fesler¹  Raphael B. Stricker² 

[1] Union Square Medical Associates, San Francisco, CA, USA;Corresponding author at: Union Square Medical Associates, 450 Sutter Street, Suite 1504, San Francisco, CA 94108, USA.;

关键词: COVID-19;    SARS-CoV-2;    Pre-exposure prophylaxis;    Hydroxychloroquine;    Vaccine;   

DOI  :  

来源: DOAJ

【 摘 要 】

To date, the COVID-19 pandemic has resulted in more than 200 million cases of SARS-CoV-2 infection and more than four million deaths world-wide. 1 Although novel COVID-19 vaccines have become clinically available, the safety and efficacy of these vaccines remains open to question. 2 Alternate approaches to prevention of disease have received little attention, and one medication, hydroxychloroquine (HCQ), has been attacked and dismissed based on flawed studies and political controversy that obscured the value of this treatment as pre-exposure prophylaxis (PrEP) for SARS-CoV-2 infection.

【 授权许可】

Unknown